Myriad Genetics: UroSuite
Nov 10, 2022
Myriad Genetics launched UroSuite, a suite of prostate cancer genetic risk assessment tests. The suite includes the Polaris Prostate Cancer Test, MyRisk Hereditary Cancer Test, BRACAnalysis CDx, and Precise Tumor Molecular Profile Test. UroSuite enables providers to order multiple Myriad tests and receive a one-sheet summary of results through an online portal, use Myriad's Precise Treatment Registry health data platform, and connect with genetic counselors and clinical experts.